Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Pharmaceuticals Revenues Up for Fourth Quarter, Year

NEW YORK, February 12 -- Genaissance Pharmaceuticals of New Haven, Conn., today announced increased revenues for the fourth quarter, ending Dec. 31, 2002, and for the year.


The company reported revenues of $2.6 million, compared to $2.2 million for the fourth quarter of 2001, and $8.1 million for the year, compared to $5.3 million for the same period a year ago.


The company had a net loss of $5.6 million for the quarter, compared to a loss of $11.4 million for the fourth quarter of 2001, and $33.3 million for the year, compared to $47.6 million for 2001.


The company reported cash, cash equivalents and securities totaling $34.2 million.


Genaissance restructed in the third quarter 2002, laying off 20 percent of its workforce.   Kevin Rakin, former president and CFO of Genaissance, replaced Gualberto Ruano, a company founder and its CEO since its inception in 1997. In the meantime, the company was able to avoid delisting on the Nasdaq exchange.   

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.